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TO THE EDITOR: In the article by Ott et al,1 the aim of the
study, KEYNOTE-028 (NCT02054806), was to evaluate the activity
and safety profile of pembrolizumab in patients with heavily pre-
treated advanced endometrial cancer (EC), a subgroup with a poor
prognosis. This article deserves some consideration to give the
study proper meaning. Unfortunately, it is a small study, as are
others that explore the activity of different agents in advanced and
metastatic EC. Of the 75 patients evaluated for programmed death
ligand 1 expression, 36 (48%) had positive tumors. According to
eligibility criteria, up to 12 patients were excluded; moreover,
another woman was excluded for lack of post-baseline assessment,
and three received no assessment at the time of the data cutoff. The
study design stated that sarcomas should be excluded; in our
opinion, even a patient with a carcinosarcoma should have been
excluded to have a more homogeneous group for this investigation.
For the same reason, the two patients who received adjuvant ra-
diotherapy should have been excluded. Therefore, only 17 patients
were eligible by clinical assessment—certainly too few to answer to
the question about clinical activity of pembrolizumab in patients
with programmed death ligand 1–positive EC.
In this article, the authors reported the promising role of
bevacizumab in EC according to available scientific data.1,2 Other
articles recently have highlighted the role of bevacizumab in this
neoplasia as well as in other gynecologic malignancies.3-6 In the
trial reported by Aghajanian et al,2 56 patients were recruited to
evaluate the activity of bevacizumab in recurrent or persistent EC.
Of 55 patients, 52 were eligible and evaluable. In the study, one
complete and six partial responses were observed (together, 13.5%
response rate); the median response duration reported was
6 months. Moreover, 21 patients (40.4%) were progression free for
at least 6 months. The median progression-free survival and overall
survival (OS) times were 4.2 and 10.5 months, respectively.
According to these data, bevacizumab use was proposed as single-
agent therapy for patients with EC who experienced progression
after standard chemotherapy.3 In the study by Ott et al,1 the 6- and
12-month progression-free survival rates were 19.9% and 14.3%,
respectively, similar to results observed by Aghajanian et al.2 The
median OS was not reached, and the 6- and 12-month OS rates
were 67.0% and 51.0%, respectively. Unfortunately, the study was
not powered to evaluate OS in this subset of patients. Because of
the small number of patients evaluable for clinical assessment, it is
difficult to correlate microsatellite instability status with clinical
outcome after therapy with pembrolizumab in these patients. Given
the results of these two studies,1,2 it seems premature to suggest
treatment with pembrolizumab in patients with EC after disease
failure with standard therapies. We await results from controlled
clinical trials, and the results of the multicohort KEYNOTE-158
trial in particular.
Federica Tomao, Pierluigi Benedetti Panici, and
Silverio Tomao
Universita` Sapienza, Rome, Italy
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Disclosures provided by the authors are available with this article at
jco.org.
REFERENCES
1. Ott PA, Bang YJ, Berton-Rigaud D, et al: Safety and antitumor activity of
pembrolizumab in advanced programmed death ligand 1–positive endometrial
cancer: Results from the KEYNOTE-028 study. J Clin Oncol 35:2535-2541, 2017
2. Aghajanian C, Sill MW, Darcy KM, et al: Phase II trial of bevacizumab in
recurrent or persistent endometrial cancer: A Gynecologic Oncology Group study.
J Clin Oncol 29:2259-2265, 2011
3. National Comprehensive Cancer Network: Clinical practice guide-
lines for uterine neoplasms. https://www.nccn.org/professionals/physician_gls/pdf/
uterine.pdf
4. Bellati F, Napoletano C, Gasparri ML, et al: Current knowledge and open
issues regarding bevacizumab in gynaecological neoplasms. Crit Rev Oncol He-
matol 83:35-46, 2012
5. Papa A, Zaccarelli E, Caruso D, et al: Targeting angiogenesis in endometrial
cancer: New agents for tailored treatments. Expert Opin Investig Drugs 25:31-49,
2016
6. Rose PG, Ali S, Moslemi-Kebria M, et al: Paclitaxel, carboplatin, and bev-
acizumab in advanced and recurrent endometrial carcinoma. Int J Gynecol Cancer
27:452-458, 2017
DOI: https://doi.org/10.1200/JCO.2017.74.4987; published at jco.org on
September 7, 2017.
n n n
Journal of Clinical Oncology, Vol 35, No 31 (November 1), 2017: pp 3633 © 2017 by American Society of Clinical Oncology 3633
VOLUME 35 • NUMBER 31 • NOVEMBER 1, 2017
Downloaded from ascopubs.org by 81.29.219.226 on November 25, 2017 from 081.029.219.226
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST
Pembrolizumab in Programmed Death Ligand 1–Positive Endometrial Cancer
The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are
self-held unless noted. I 5 Immediate Family Member, Inst 5 My Institution. Relationships may not relate to the subject matter of this manuscript. For more
information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.
Federica Tomao
No relationship to disclose
Pierluigi Benedetti Panici
Speakers’ Bureau: AstraZeneca, PharmaMar
Silverio Tomao
No relationship to disclose
© 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Correspondence
Downloaded from ascopubs.org by 81.29.219.226 on November 25, 2017 from 081.029.219.226
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
